Therefore we examined the therapeutic effect of brigatinib as a single agent in BalbC/NUDE mice injected with human neuroblastoma CLB-BAR cells, (ALK Δ4-11 and MYCN amplified, ALK addicted) subcutaneously. The gene discussed is ALK; the disease is neuroblastoma.